[The differences in the estimation of depression severity by psychiatrists and patients during the combined treatment with agomelatine (a multicenter study "EMOTSIA")].

Autor:	Medvedev VE; Russian University of People's Friendship Moscow, Russia., Retiunsky KY; Ural State Medical University, Yekaterinburg, Russia., Ovchinnikov AA; Novosibirsk State Medical University, Novosibirsk, Russia., Barylnik YB; Razumovsky Saratov State Medical University, Saratov, Russia., Shmilovich AA; Pirogov National Research Medical University, Moscow, Russia., Antokhin EY; Orenburg State Medical University, Orenburg, Russia., Usov GM; Omsk State Medical Academy, Omsk, Russia., Cheremin RA; Organizatsion, Methodical and Consultation Unit for and Psychiatry And Suicidology Public Health Department, Moscow, Russia., Poletsky VM; South Ural State Medical University, Chelyabinsk, Russia., Onegin AV; Murmansk Regional Psychoneurological Dispensary, Murmansk, Russia., Kireeva IP; Pirogov National Research Medical University, Moscow, Russia., Frolova VI; Russian University of People's Friendship Moscow, Russia., Filippova NV; Razumovsky Saratov State Medical University, Saratov, Russia., Antonova AA; Razumovsky Saratov State Medical University, Saratov, Russia., Deeva MA; Razumovsky Saratov State Medical University, Saratov, Russia., Onegina DA; Murmansk Regional Psychoneurological Dispensary, Murmansk, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2016; Vol. 116 (11), pp. 26-34.
DOI:	10.17116/jnevro201611611126-34
Abstrakt:	Aim: To compare the prognosis of depression severity estimated by the physician and by the patient based on the treatment outcome. Material and Methods: One hundred and seven patients with depression were examined. Mental status was assessed with HАМ-D, SHAPS, CGI-S, CGI-I, PGI-S, PGI-I and VAS. A data analysis was performed. Results: There were differences in the estimation of depression severity by psychiatrists and patients. Moreover, the scores on HАМ-D and CGI-S were not consistent when assessed by psychiatrists. As the severity of depression decreased and patient's state improved during the treatment with agomelatine (valdoxan), the assessments of the changes by the psychiatrist and the patient became similar. Conclusion: Agomelatine (valdoxan) is effective and tolerable in the treatment of depression of any severity. The differences between the psychiatrist's and patient's estimation of the depression severity at baseline using different psychometric scales can level the prognostic value of treatment outcome.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu